Subscribe to our newsletter to receive the latest product updates and special offers

HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite
Theme 		Help

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Open in Screener

APRE

Aprea Therapeutics Inc

Last Close
May 02 • 04:00PM ET
5.45
Dollar change
+0.20
Percentage change
3.81 		%
Held by: VTI VXF DFAT DFSU DFAC
Index- P/E- EPS (ttm)-4.00 Insider Own11.79% Shs Outstand5.43M Perf Week1.87%
Market Cap29.59M Forward P/E- EPS next Y-1.53 Insider Trans2.68% Shs Float4.79M Perf Month-18.29%
Income-14.29M PEG- EPS next Q-0.76 Inst Own17.09% Short Float2.01% Perf Quarter-4.39%
Sales0.58M P/S51.02 EPS this Y34.26% Inst Trans-47.21% Short Ratio2.96 Perf Half Y54.04%
Book/sh4.54 P/B1.20 EPS next Y41.21% ROA-54.11% Short Interest0.10M Perf Year37.45%
Cash/sh3.98 P/C1.37 EPS next 5Y- ROE-63.19% 52W Range2.78 - 8.85 Perf YTD15.96%
Dividend Est.- P/FCF- EPS past 5Y23.41% ROI-78.22% 52W High-38.39% Beta1.07
Dividend TTM- Quick Ratio5.14 Sales past 5Y0.00% Gross Margin- 52W Low96.04% ATR (14)0.40
Dividend Ex-Date- Current Ratio5.14 EPS Y/Y TTM96.52% Oper. Margin-2652.80% RSI (14)45.44 Volatility3.97% 6.79%
Employees7 Debt/Eq0.00 Sales Y/Y TTM- Profit Margin-2449.59% Recom1.00 Target Price15.67
Option/ShortNo / Yes LT Debt/Eq0.00 EPS Q/Q94.99% Payout- Rel Volume0.08 Prev Close5.25
Sales Surprise-91.45% EPS Surprise-19.99% Sales Q/Q- EarningsMar 26 BMO Avg Volume32.48K Price5.45
SMA20-3.20% SMA50-13.94% SMA20012.81% Trades Volume2,607 Change3.81%
Date Action Analyst Rating Change Price Target Change
Dec-28-20Downgrade Robert W. Baird Outperform → Neutral
Dec-16-20Initiated Berenberg Buy $37
Sep-29-20Resumed JP Morgan Neutral $25
Jun-22-20Initiated H.C. Wainwright Neutral $30
Apr-21-20Initiated Robert W. Baird Outperform $45
Oct-28-19Initiated RBC Capital Mkts Outperform $33
Oct-28-19Initiated Morgan Stanley Equal-Weight $23
Oct-28-19Initiated JP Morgan Neutral $23
May-02-24 09:15AM
Aprea Therapeutics Announces Appointment of Nadeem Q. Mirza, M.D., M.P.H. as Chief Medical Officer and Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire)
Apr-10-24 12:00PM
Aprea Therapeutics Announces Presentations on its Next Generation WEE1 Inhibitor, APR-1051, and A Novel Macrocyclic ATR Inhibitor, ATRN-119, at AACR Annual Meeting 2024
(GlobeNewswire)
Mar-26-24 01:53PM
APRE Stock Earnings: Aprea Therapeutics Misses EPS, Misses Revenue for Q4 2023
(InvestorPlace)
07:45AM
Aprea Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update
(GlobeNewswire)
Mar-11-24 08:30AM
Aprea Therapeutics Announces Private Placement Financing of up to $34.0 Million
(GlobeNewswire) -5.05%
08:29AM Loading…
08:29AM
Aprea Therapeutics Announces FDA Clearance of IND for APR-1051, its Next Generation WEE1 Kinase Inhibitor for Cyclin E Overexpressing Cancers
(GlobeNewswire)
Mar-05-24 04:45PM
Aprea Therapeutics Announces Acceptance of Abstracts at American Association of Cancer Research Annual Meeting 2024
(GlobeNewswire)
Feb-06-24 08:01AM
Aprea Therapeutics Announces Submission of IND Application for APR-1051, a Next Generation WEE1 Kinase Inhibitor
(GlobeNewswire) +11.97%
Jan-30-24 08:00AM
Aprea Therapeutics to Present at DDR Inhibitors Summit 2024
(GlobeNewswire)
Jan-04-24 04:05PM
Aprea Therapeutics Provides Corporate Update and Announces Development Plans for 2024
(GlobeNewswire)
Nov-09-23 04:05PM
Aprea Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update
(GlobeNewswire)
Oct-24-23 08:00AM
Aprea Therapeutics to Host a Key Opinion Leader (KOL) Event on its Synthetic Lethality (SL) and DNA Damage Response (DDR) Pathways
(GlobeNewswire)
Oct-16-23 08:30AM
Aprea Unveils Initial Clinical Data on ATRi, ATRN-119, and Pre-Clinical Data on WEE1i, ATRN-1051, at AACR-NCI-EORTC International Conference Supporting Highly Differentiated Synthetic Lethality Portfolio
(GlobeNewswire)
Sep-19-23 08:00AM
Aprea Therapeutics Announces Two Posters at the Upcoming 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
(GlobeNewswire)
Sep-11-23 08:00AM
Aprea Announces Preclinical Data Supporting Highly Differentiated WEE1 Inhibitor, ATRN-1051, Relative To Other WEE1 Inhibitors
(GlobeNewswire)
04:05PM Loading…
Sep-06-23 04:05PM
Aprea Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
(GlobeNewswire)
Aug-24-23 07:30AM
Aprea Therapeutics Appoints Dr. Jean-Pierre Bizzari to its Board of Directors and Names Dr. Richard Peters as Chairman
(GlobeNewswire)
Aug-10-23 07:30AM
Aprea Therapeutics Reports Second Quarter 2023 Financial Results and Provides Update on Business Operations
(GlobeNewswire)
Jun-14-23 08:00AM
Aprea Therapeutics to Present at Maxim Virtual Healthcare Conference
(GlobeNewswire)
May-30-23 08:30AM
Aprea Therapeutics to Present at BIO International Convention
(GlobeNewswire) +11.76%
May-15-23 04:05PM
Aprea Therapeutics Reports First Quarter 2023 Financial Results and Provides Update on Business Operations
(GlobeNewswire) -7.34%
May-08-23 08:00AM
Aprea Therapeutics Appoints Gabriela Gruia, M.D. to Board of Directors
(GlobeNewswire)
Apr-24-23 09:55AM
Bears are Losing Control Over Aprea Therapeutics, Inc. (APRE), Here's Why It's a 'Buy' Now
(Zacks)
Apr-04-23 12:00PM
All You Need to Know About Aprea Therapeutics, Inc. (APRE) Rating Upgrade to Buy
(Zacks) -5.01%
Mar-30-23 04:05PM
Aprea Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Update on Business Operations
(GlobeNewswire)
Mar-16-23 08:00AM
Aprea Therapeutics Announces Presentation of Preclinical Data on Pipeline Programs at the AACR 2023 Annual Meeting
(GlobeNewswire)
Mar-07-23 08:00AM
Aprea Therapeutics to Present at Oppenheimers 33rd Annual Healthcare Conference
(GlobeNewswire) -5.26%
Mar-01-23 04:05PM
Aprea Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
(GlobeNewswire)
Feb-27-23 04:05PM
Aprea Therapeutics Announces Closing of $5.5 Million Underwritten Public Offering of Common Stock
(GlobeNewswire)
Feb-22-23 08:41PM
Aprea Therapeutics Announces Pricing of $5.5 Million Underwritten Public Offering of Common Stock
(GlobeNewswire)
04:05PM Loading…
04:05PM
Aprea Therapeutics Announces Proposed Public Offering of Common Stock
(GlobeNewswire)
Feb-15-23 08:00AM
Aprea Therapeutics Announces Phase II SBIR Award from the National Cancer Institute (NCI)
(GlobeNewswire)
Feb-13-23 07:00AM
Aprea Therapeutics Announces One-for-Twenty Reverse Stock Split
(GlobeNewswire)
Jan-30-23 08:00AM
Aprea Therapeutics Appoints John Hamill as Chief Financial Officer
(GlobeNewswire)
Jan-19-23 08:00AM
Aprea Therapeutics to Participate in 6th Annual DNA Damage and Response (DDR) Inhibitors Summit
(GlobeNewswire) -7.57%
Jan-12-23 09:56AM
Aprea (APRE) Rises on Advancing Lead Drug to Clinical Studies
(Zacks)
Jan-11-23 08:00AM
Aprea Therapeutics Announces Dosing of First Patient in Phase 1/2a Clinical Trial of Oral ATR Inhibitor ATRN-119 for the Treatment of Advanced Solid Tumors
(GlobeNewswire) +11.99%
Nov-09-22 04:15PM
Aprea Therapeutics Reports Third Quarter 2022 Financial Results and Provides Update on Business Operations
(GlobeNewswire)
Sep-22-22 06:00PM
Aprea Therapeutics Announces Poster Presentation at the 2022 Rivkin Center and American Association for Cancer (AACR) Virtual Ovarian Cancer Research Seminar Series
(GlobeNewswire)
Sep-08-22 08:00AM
Aprea Therapeutics to Participate in the 2022 H.C. Wainwright Global Investment Conference
(GlobeNewswire)
Aug-11-22 04:15PM
Aprea Therapeutics Reports Second Quarter 2022 Financial Results and Provides Update on Business Operations
(GlobeNewswire)
Aug-02-22 08:00AM
Aprea Therapeutics to Participate in the 2022 Wedbush PacGrow Healthcare Conference
(GlobeNewswire)
May-19-22 06:30AM
The Petri Dish: Taiho acquires Cullinan cancer subsidiary in $405M deal
(American City Business Journals)
May-16-22 09:21AM
Aprea Therapeutics Announces Acquisition of Atrin Pharmaceuticals Inc. and Reports First Quarter 2022 Financial Results
(GlobeNewswire) -19.09%
Mar-15-22 04:15PM
Aprea Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Update on Business Operations
(GlobeNewswire) +5.45%
Mar-02-22 04:41AM
Is Aprea Therapeutics (NASDAQ:APRE) In A Good Position To Deliver On Growth Plans?
(Simply Wall St.)
Jan-14-22 10:00AM
Aprea Therapeutics, Inc. (APRE) Loses 21.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
(Zacks)
Jan-06-22 08:00AM
Aprea Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13, 2022
(GlobeNewswire)
Dec-14-21 08:00AM
Recap and Update of Positive Data from Three Presentations in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Presented at the 2021 American Society of Hematology (ASH) Annual Meeting
(GlobeNewswire) -10.05%
Dec-13-21 08:00AM
Aprea Therapeutics Presents Primary Analysis from Phase 2 Trial of Eprenetapopt + Azacitidine for Post-Transplant Maintenance Therapy in TP53 Mutant MDS and AML at the 2021 American Society of Hematology (ASH) Annual Meeting
(GlobeNewswire) -10.85%
Dec-10-21 10:30AM
Aprea (APRE) Reports FDA Removal of Clinical Hold on Study
(Zacks)
Dec-09-21 12:30PM
FDA Lifts Clinical Hold On Aprea's Eprenetapopt Trial In Myeloid Malignancies
(Benzinga)
08:00AM
Aprea Therapeutics Announces Removal of FDA Clinical Hold on Eprenetapopt in Lymphoid Malignancies
(GlobeNewswire)
Nov-08-21 04:15PM
Aprea Therapeutics Reports Third Quarter 2021 Financial Results and Provides Update on Business Operations
(GlobeNewswire)
Nov-04-21 04:15PM
Aprea Therapeutics to Present Data from Clinical Trials Evaluating Eprenetapopt at 63rd American Society of Hematology Annual Meeting
(GlobeNewswire)
Sep-21-21 08:39AM
Aprea Therapeutics Stock Jumps After Eprenetapopt Combo Data Presentation At ESMO
(Benzinga)
07:01AM
18 Stocks Moving in Tuesday's Pre-Market Session
(Benzinga)
Sep-20-21 04:15PM
Aprea Therapeutics Presents Data From Phase 1/2 Trial of Eprenetapopt (APR-246) in Advanced Solid Tumors at ESMO Congress 2021
(GlobeNewswire)
08:42AM
Is the Options Market Predicting a Spike in Aprea Therapeutics (APRE) Stock?
(Zacks)
Sep-14-21 08:00AM
Aprea Therapeutics to Present Data from Phase 1/2 Trial of Eprenetapopt in Advanced Solid Tumors at ESMO Congress 2021
(GlobeNewswire)
Sep-03-21 07:21AM
Are Institutions Heavily Invested In Aprea Therapeutics, Inc.'s (NASDAQ:APRE) Shares?
(Simply Wall St.)
Aug-12-21 04:15PM
Aprea Therapeutics Reports Second Quarter 2021 Financial Results and Provides Update on Business Operations
(GlobeNewswire)
06:00AM
Aprea Therapeutics Announces Clinical Hold on Lymphoid Malignancy Program
(GlobeNewswire)
Aug-05-21 05:00PM
Aprea Therapeutics Announces a Partial Clinical Hold on Myeloid Malignancy Programs
(GlobeNewswire)
Jul-21-21 08:00AM
Aprea Therapeutics Announces Positive Results from Phase 2 Trial of Eprenetapopt + Azacitidine for Post-Transplant Maintenance Therapy in TP53 Mutant MDS and AML
(GlobeNewswire) -5.52%
Jun-18-21 08:34AM
Implied Volatility Surging for Aprea (APRE) Stock Options
(Zacks)
Jun-17-21 09:19AM
Aprea (APRE) Stock Rises as Leukemia Triplet Meets Study Goal
(Zacks) -6.32%
Jun-16-21 09:24AM
Aprea Therapeutics Stock Is Trading Higher As Eprenetapopt Triplet Therapy Achieves 37% CR Rate In Leukemia Patients
(Benzinga) +10.93%
08:00AM
Aprea Therapeutics Announces Phase 1/2 Trial of Eprenetapopt + Venetoclax + Azacitidine in TP53 Mutant AML Meets Complete Remission Primary Efficacy Endpoint
(GlobeNewswire)
Jun-13-21 12:45PM
Is Aprea Therapeutics, Inc. (APRE) A Good Stock To Buy?
(Insider Monkey)
Jun-04-21 01:47AM
Is Aprea Therapeutics (NASDAQ:APRE) In A Good Position To Invest In Growth?
(Simply Wall St.)
May-21-21 06:00AM
Aprea Therapeutics to Participate in the 2021 Oppenheimer Rare & Orphan Disease Summit
(GlobeNewswire)
May-18-21 06:00AM
Aprea Therapeutics to Participate in the 2021 RBC Capital Markets Global Healthcare Conference
(GlobeNewswire)
May-06-21 04:15PM
Aprea Therapeutics Reports First Quarter 2021 Financial Results and Provides Update on Business Operations
(GlobeNewswire)
Apr-16-21 09:15AM
Aprea Therapeutics to Host Virtual R&D Day on April 22, 2021
(GlobeNewswire) +7.64%
Apr-08-21 11:15AM
Aprea Therapeutics Receives FDA Orphan Drug Designation for Eprenetapopt for the Treatment of Acute Myeloid Leukemia (AML)
(GlobeNewswire) +13.64%
Mar-16-21 04:15PM
Aprea Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Update on Business Operations
(GlobeNewswire)
Feb-16-21 08:04AM
Is Aprea Therapeutics, Inc. (NASDAQ:APRE) Popular Amongst Institutions?
(Simply Wall St.)
Jan-22-21 12:00PM
What Makes Aprea Therapeutics, Inc. (APRE) a New Buy Stock
(Zacks)
Jan-08-21 08:00AM
Aprea Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021
(GlobeNewswire)
Dec-30-20 11:40AM
Biotech Stock Roundup: REGN Provides COVID-19 Updates, MYOV Partners With PFE & More
(Zacks)
Dec-29-20 07:24PM
Dont Go Bargain Hunting on Aprea Stock, Says Analyst
(TipRanks) -8.18%
10:32AM
Aprea (APRE) Plunges as Late-Stage MDS Study Fails to Meet Goal
(Zacks)
Dec-28-20 04:57PM
10 Biggest Stock Gainers and Losers Today
(Insider Monkey) -78.08%
02:22PM
Aprea Shares Slump After Cancer-Drug Trial Misses Key Goal
(TheStreet.com)
08:00AM
Aprea Therapeutics Announces Results of Primary Endpoint from Phase 3 Trial of Eprenetapopt in TP53 Mutant Myelodysplastic Syndromes (MDS)
(GlobeNewswire)
Dec-10-20 10:33PM
Is APRE A Good Stock To Buy Now?
(Insider Monkey)
Nov-30-20 08:00AM
Aprea Therapeutics Receives FDA Fast Track Designation for Eprenetapopt in the Treatment of TP53 Mutant Acute Myeloid Leukemia (AML)
(GlobeNewswire)
Nov-23-20 10:00AM
3 Stocks with Jaw-Dropping Growth Potential
(Motley Fool)
Nov-19-20 08:00AM
Aprea Therapeutics to Participate in the 32nd Annual Piper Sandler Healthcare Conference
(GlobeNewswire)
Nov-05-20 04:15PM
Aprea Therapeutics Reports Third Quarter 2020 Financial Results and Provides Update on Business Operations
(GlobeNewswire) -8.52%
Oct-30-20 04:00AM
Aprea Therapeutics to Highlight Changing Treatment Paradigm in MDS as well as Development Pipeline Progress at Virtual R&D Day Today
(GlobeNewswire)
Oct-14-20 08:00AM
Aprea Therapeutics Launches Disease Awareness Website for Healthcare Professionals, p53reactivation.com
(GlobeNewswire)
Oct-07-20 08:00AM
Aprea Therapeutics Receives OK from FDA to Initiate Phase 1 Clinical Studies for Next-Generation Mutant p53 Reactivator, APR-548
(GlobeNewswire) +8.85%
Sep-29-20 08:00AM
Aprea Therapeutics Appoints Michael A. Kelly to Board of Directors
(GlobeNewswire)
06:28AM
Should You Take Comfort From Insider Transactions At Aprea Therapeutics, Inc. (NASDAQ:APRE)?
(Simply Wall St.)
Sep-18-20 08:00AM
Aprea Therapeutics Promotes Gregory S. Wessels to Chief Commercial Officer and Announces Governance Changes
(GlobeNewswire)
Sep-03-20 08:00AM
Aprea Therapeutics to Present at Upcoming Investor Conferences
(GlobeNewswire)
Aug-11-20 04:15PM
Aprea Therapeutics Reports Second Quarter 2020 Financial Results and Provides Update on Business Operations
(GlobeNewswire) -7.60%
Jul-16-20 07:00AM
Aprea Therapeutics Announces Expansion of Clinical Trial Evaluating Eprenetapopt for the Front-Line Treatment of TP53 Mutant Acute Myeloid Leukemia (AML)
(GlobeNewswire) +5.40%
Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the provision of cancer therapeutics. It is involved in the development and commercialization of novel cancer therapeutics that reactivate mutant p53 tumor suppressor protein. The company was founded by Vladimir Bykov, Klas Gota Wiman, Staffan Stromblad, Natalia Issaeva, Galina Selivanova, and Wen Jie Bao in 2002 and is headquartered in Doylestown, PA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Seizinger Bernd R.DirectorMar 13 '24Buy7.296,86050,00933,685Mar 14 08:53 PM
HENNEMAN JOHN B IIIDirectorMar 13 '24Buy7.296,86050,0098,139Mar 14 08:52 PM
Gilad OrenPresident, CEOMar 13 '24Buy7.292,00014,580324,770Mar 14 08:51 PM
Hamill John P.SrVP/CFO/Prin Fin & Acct OfcrMar 13 '24Buy7.291,0107,36315,503Mar 14 08:54 PM
Seizinger Bernd R.DirectorJun 07 '23Buy3.686,02922,19226,325Jun 08 04:34 PM
Seizinger Bernd R.DirectorJun 06 '23Buy3.634,06814,76420,296Jun 08 04:34 PM
open in screener | open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
Open in Screener

RCM

R1 RCM Inc.

Last Close
May 02 • 04:00PM ET
12.45
Dollar change
+0.09
Percentage change
0.73 		%
RCM R1 RCM Inc. daily Stock Chart
Held by: IJH VTI VB VXF VBK IJJ VHT SCHM IWR IWD
Index- P/E1753.52 EPS (ttm)0.01 Insider Own64.20% Shs Outstand420.20M Perf Week5.33%
Market Cap5.23B Forward P/E29.23 EPS next Y0.43 Insider Trans-0.00% Shs Float150.47M Perf Month-1.74%
Income3.30M PEG- EPS next Q0.03 Inst Own39.33% Short Float7.33% Perf Quarter15.81%
Sales2.25B P/S2.32 EPS this Y-67.54% Inst Trans1.24% Short Ratio3.26 Perf Half Y5.60%
Book/sh6.55 P/B1.90 EPS next Y80.57% ROA0.07% Short Interest11.04M Perf Year-20.14%
Cash/sh0.41 P/C30.14 EPS next 5Y-2.50% ROE0.12% 52W Range8.87 - 18.70 Perf YTD17.79%
Dividend Est.- P/FCF22.02 EPS past 5Y- ROI0.08% 52W High-33.44% Beta0.86
Dividend TTM- Quick Ratio1.81 Sales past 5Y21.41% Gross Margin21.32% 52W Low40.36% ATR (14)0.37
Dividend Ex-Date- Current Ratio1.81 EPS Y/Y TTM106.48% Oper. Margin11.81% RSI (14)52.59 Volatility2.98% 2.64%
Employees30000 Debt/Eq0.63 Sales Y/Y TTM24.76% Profit Margin0.15% Recom1.60 Target Price16.93
Option/ShortYes / Yes LT Debt/Eq0.60 EPS Q/Q103.54% Payout0.00% Rel Volume0.28 Prev Close12.36
Sales Surprise-0.31% EPS Surprise171.16% Sales Q/Q7.84% EarningsMay 08 BMO Avg Volume3.38M Price12.45
SMA201.38% SMA50-3.32% SMA200-3.75% Trades Volume961,568 Change0.73%
Date Action Analyst Rating Change Price Target Change
Apr-10-24Downgrade KeyBanc Capital Markets Overweight → Sector Weight
Mar-20-24Upgrade Citigroup Neutral → Buy $16
Feb-26-24Initiated Leerink Partners Outperform $14
Jan-03-24Initiated Barclays Overweight $14
Dec-15-23Upgrade Morgan Stanley Equal-Weight → Overweight $17.50 → $17
Dec-13-23Downgrade JP Morgan Overweight → Neutral $20 → $11
Oct-19-23Upgrade Truist Hold → Buy $18
Sep-22-23Initiated Citigroup Buy $20
Aug-15-23Initiated Cantor Fitzgerald Overweight $20
Apr-12-23Initiated Stephens Overweight $18
Show Previous Ratings
Apr-30-24 05:05PM
R1 RCM to Present at the 2024 Bank of America Securities Health Care Conference
(GlobeNewswire)
Apr-20-24 09:16AM
10 Best Healthcare Stocks to Buy Under $20
(Insider Monkey)
Apr-01-24 05:00PM
R1 RCM to Release First Quarter 2024 Results on May 8, 2024
(GlobeNewswire)
Mar-27-24 08:00AM
R1 Releases Fourth Annual Environmental, Social and Governance (ESG) Report
(GlobeNewswire)
Mar-11-24 08:00AM
R1 RCM Forms Special Committee to Evaluate Strategic Alternatives
(GlobeNewswire)
06:38AM Loading…
Feb-29-24 06:38AM
What Makes R1 RCM (RCM) a Lucrative Investment?
(Insider Monkey)
04:32AM
R1 RCM Inc. (RCM) Reports Notable Revenue and EBITDA Growth in Q4 and Full Year 2023
(GuruFocus.com)
Feb-28-24 08:45AM
R1 RCM Inc. (NASDAQ:RCM) Q4 2023 Earnings Call Transcript
(Insider Monkey)
Feb-27-24 11:11PM
Q4 2023 R1 RCM Inc Earnings Call
(Thomson Reuters StreetEvents)
10:00AM
Compared to Estimates, R1 RCM Inc. (RCM) Q4 Earnings: A Look at Key Metrics
(Zacks)
08:15AM
R1 RCM Inc. (RCM) Reports Break-Even Earnings for Q4
(Zacks)
07:00AM
R1 RCM Reports Fourth Quarter and Full Year 2023 Results
(GlobeNewswire)
Feb-26-24 01:13PM
R1 RCM Holders Discuss Take Private of Health-Care IT Firm
(Bloomberg) +25.14%
08:30AM
Should You Buy R1 RCM (RCM) Ahead of Earnings?
(Zacks)
04:29AM
R1 RCM receives takeover offer from New Mountain
(Healthcare Dive)
09:15AM Loading…
Feb-22-24 09:15AM
Ahead of R1 RCM Inc. (RCM) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics
(Zacks)
Feb-20-24 10:00AM
R1 RCM Inc. (RCM) Reports Next Week: Wall Street Expects Earnings Growth
(Zacks)
Feb-16-24 05:00PM
R1 RCM to Present at Upcoming Investor Conferences
(GlobeNewswire)
Feb-07-24 08:00AM
R1 Wins Multiple Best in KLAS Awards for Third Straight Year
(GlobeNewswire)
Jan-17-24 04:05PM
R1 RCM Completes Acquisition of Acclara, Providence's Modular Services Business
(GlobeNewswire)
Jan-08-24 07:00AM
R1 RCM Announces Preliminary Fourth Quarter Results
(GlobeNewswire)
Dec-27-23 06:41PM
13 Most Promising Future Stocks To Buy According To Hedge Funds
(Insider Monkey)
Dec-21-23 05:00PM
R1 RCM to Present at the 42nd Annual J.P. Morgan Healthcare Conference
(GlobeNewswire)
Dec-06-23 06:00AM
R1 RCM to Acquire Acclara
(GlobeNewswire)
Dec-05-23 03:36PM
Activist Short Seller Says R1 RCM (RCM) Creatively Manipulates Revenues- Hagens Berman
(GlobeNewswire) -6.86%
Dec-04-23 08:00AM
R1 Completes Restatement of Previously Issued Financial Statements
(GlobeNewswire) +8.56%
Nov-29-23 11:50AM
Lowey Dannenberg, P.C. is Investigating R1 RCM Inc. ( RCM or the Company ) (NASDAQ: RCM) for Potential Violations of the Federal Securities Laws
(GlobeNewswire)
Nov-27-23 10:55AM
Activist Short Seller Says R1 RCM (RCM) Creatively Manipulates Revenues- Hagens Berman
(GlobeNewswire)
Nov-20-23 12:53PM
Hagens Berman says Activist Short Seller Says R1 RCM (RCM) Creatively Manipulates Revenues
(GlobeNewswire)
Nov-17-23 04:00PM
R1 RCM Receives Notice of Filing Delinquency from Nasdaq
(GlobeNewswire)
03:21PM Loading…
Nov-13-23 03:21PM
Hagens Berman says Activist Short Seller Says R1 RCM (RCM) Creatively Manipulates Revenues
(GlobeNewswire)
07:30AM
R1 RCM to Restate Certain Previously Issued Financial Statements Due to Errors in Accounting for Expenses Associated with Historical Acquisitions
(GlobeNewswire)
Nov-07-23 05:00PM
R1 RCM to Present at Upcoming Investor Conferences
(GlobeNewswire)
Nov-06-23 12:09PM
R1 RCM (RCM) Accused of Manipulating Revenues: Hagens Berman, National Trial Attorneys, Encourages R1 RCM (RCM) Investors with Substantial Losses to Contact Firm's Attorneys
(GlobeNewswire) -7.29%
Nov-05-23 06:06PM
R1 RCM Inc. (NASDAQ:RCM) Q3 2023 Earnings Call Transcript
(Insider Monkey)
Nov-02-23 11:00AM
R1 RCM Inc. (RCM) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
(Zacks) -10.25%
09:27AM
R1 RCM Inc (RCM) Reports 15.5% Revenue Increase in Q3 2023
(GuruFocus.com)
07:05AM
R1 RCM expands collaboration with Microsoft to accelerate integration of Azure OpenAI Service across the R1 enterprise
(GlobeNewswire)
07:00AM
R1 RCM Reports Third Quarter 2023 Results
(GlobeNewswire)
Oct-31-23 02:09PM
Hagens Berman says Activist Short Seller Says R1 RCM (RCM) Creatively Manipulates Revenues
(GlobeNewswire)
Oct-30-23 10:00AM
Earnings Preview: Adeia (ADEA) Q3 Earnings Expected to Decline
(Zacks)
Oct-29-23 09:00PM
Bragar Eagel & Squire, P.C. Is Investigating GrafTech, and R1 RCM and Encourages Investors to Contact the Firm
(GlobeNewswire)
Oct-23-23 09:00PM
Bragar Eagel & Squire, P.C. Is Investigating Wiley, and R1 RCM and Encourages Investors to Contact the Firm
(GlobeNewswire)
07:52PM
Hagens Berman Says Activist Short Seller Says R1 RCM (RCM) Creatively Manipulates Revenues
(GlobeNewswire)
Oct-20-23 09:09PM
R1 RCM Inc: Company Investigated by the Portnoy Law Firm
(GlobeNewswire)
Oct-17-23 12:00PM
R1 RCM Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm
(GlobeNewswire)
Oct-16-23 05:00PM
R1 RCM to Release Third Quarter 2023 Results on November 2
(GlobeNewswire) -8.26%
11:43AM
Unveiling R1 RCM (RCM)'s Value: Is It Really Priced Right? A Comprehensive Guide
(GuruFocus.com)
Oct-06-23 09:35AM
Down -18.93% in 4 Weeks, Here's Why R1 RCM Inc. (RCM) Looks Ripe for a Turnaround
(Zacks)
Sep-26-23 12:12PM
Unraveling the Future of R1 RCM Inc (RCM): A Deep Dive into Key Metrics
(GuruFocus.com)
11:59AM
Assessing the True Worth of R1 RCM (RCM): A Comprehensive Guide to its Valuation
(GuruFocus.com)
Sep-20-23 10:13AM
R1 RCM Inc. sees growth despite trading at discount
(Investing.com)
Sep-12-23 08:36AM
Implied Volatility Surging for R1 RCM (RCM) Stock Options
(Zacks)
Aug-15-23 09:59AM
Redfin upgraded, CSSE downgraded: Wall Street's top analyst calls
(The Fly)
Aug-02-23 10:00AM
Compared to Estimates, R1 RCM Inc. (RCM) Q2 Earnings: A Look at Key Metrics
(Zacks)
08:15AM
R1 RCM Inc. (RCM) Reports Break-Even Earnings for Q2
(Zacks)
07:00AM
R1 RCM Reports Second Quarter 2023 Results
(GlobeNewswire)
Jul-31-23 05:00PM
R1 RCM to Present at Upcoming Investor Conferences
(GlobeNewswire)
Jul-17-23 04:18PM
12 Best NASDAQ Stocks Under $20
(Insider Monkey)
Jul-14-23 09:00AM
Positive week for R1 RCM Inc. (NASDAQ:RCM) institutional investors who lost 23% over the past year
(Simply Wall St.)
Jul-12-23 05:00PM
R1 RCM to Release Second Quarter 2023 Results on August 2
(GlobeNewswire)
Jun-21-23 08:00PM
RCM: Raising target price to $19.00
(Argus Research)
Jun-08-23 09:41AM
Why Investors Shouldn't Be Surprised By R1 RCM Inc.'s (NASDAQ:RCM) P/S
(Simply Wall St.)
May-22-23 03:32PM
Is It Too Late To Consider Buying R1 RCM Inc. (NASDAQ:RCM)?
(Simply Wall St.)
May-06-23 08:09AM
R1 RCM Inc. Beat Analyst Profit Forecasts, And Analysts Have New Estimates
(Simply Wall St.)
May-04-23 08:15AM
R1 RCM Inc. (RCM) Reports Break-Even Earnings for Q1
(Zacks)
07:00AM
R1 RCM Reports First Quarter 2023 Results
(GlobeNewswire)
May-02-23 05:00PM
R1 RCM to Present at Upcoming Investor Conferences
(GlobeNewswire)
Apr-27-23 10:02AM
Earnings Preview: R1 RCM Inc. (RCM) Q1 Earnings Expected to Decline
(Zacks)
Apr-26-23 08:00PM
RCM: What does Argus have to say about RCM?
(Argus Research)
06:45PM
Nov Inc. (NOV) Surpasses Q1 Earnings and Revenue Estimates
(Zacks)
Apr-18-23 05:00PM
R1 RCM to Release First Quarter 2023 Results on May 4
(GlobeNewswire)
Apr-11-23 07:17AM
Returns Are Gaining Momentum At R1 RCM (NASDAQ:RCM)
(Simply Wall St.)
Mar-17-23 08:56AM
Those who invested in R1 RCM (NASDAQ:RCM) five years ago are up 84%
(Simply Wall St.)
Mar-01-23 08:00AM
R1 RCM Issues 2022 Environmental, Social, and Governance Report
(GlobeNewswire)
Feb-28-23 07:03AM
R1 RCM (RCM) Faced Multiple Challenges in Q4
(Insider Monkey)
Feb-22-23 06:56AM
Daily Vickers Top Buyers & Sellers for 02/22/2023
(Argus Research)
Feb-21-23 05:00PM
R1 RCM to Present at Upcoming Investor Conferences
(GlobeNewswire)
Feb-18-23 07:15AM
R1 RCM Full Year 2022 Earnings: EPS Misses Expectations
(Simply Wall St.)
Feb-16-23 12:40PM
Why R1 RCM Stock Is Surging Today
(Motley Fool)
08:15AM
R1 RCM Inc. (RCM) Reports Q4 Loss, Tops Revenue Estimates
(Zacks)
07:00AM
R1 RCM Reports Fourth Quarter and Full Year 2022 Results
(GlobeNewswire)
Feb-08-23 08:30AM
R1 RCM & Cloudmed Ranked #1 by KLAS in Multiple Categories for 2023
(GlobeNewswire)
Jan-30-23 05:35AM
Following a 41% decline over last year, recent gains may please R1 RCM Inc. (NASDAQ:RCM) institutional owners
(Simply Wall St.)
Jan-26-23 05:00PM
R1 RCM to Release Fourth Quarter 2022 Results on February 16
(GlobeNewswire)
Jan-09-23 01:39PM
R1 RCM Inc. (NASDAQ:RCM) Shares Could Be 37% Below Their Intrinsic Value Estimate
(Simply Wall St.)
Jan-05-23 04:15PM
R1 RCM Announces Leadership Appointments; Reaffirms 2022 Guidance and Announces 2023 Outlook
(GlobeNewswire)
Dec-22-22 05:00PM
R1 RCM to Present at the 41st Annual J.P. Morgan Health Care Conference
(GlobeNewswire)
Dec-20-22 06:07AM
Is R1 RCM Inc.'s (NASDAQ:RCM) Stock Price Struggling As A Result Of Its Mixed Financials?
(Simply Wall St.)
Nov-29-22 04:47PM
Why Shares of R1 RCM rose 10% on Tuesday
(Motley Fool) +9.85%
Nov-28-22 06:15AM
7 F-Rated Stocks to Sell Before We Reach Christmas
(InvestorPlace)
Nov-09-22 06:17AM
Is It Too Late To Consider Buying R1 RCM Inc. (NASDAQ:RCM)?
(Simply Wall St.) -6.88%
Nov-08-22 01:31PM
R1 RCM stock suffers record selloff of more than 51% after rare profit miss, physician customer missed payment
(MarketWatch) -49.76%
08:25AM
R1 RCM Inc. (RCM) Reports Q3 Loss, Misses Revenue Estimates
(Zacks)
07:00AM
R1 RCM Reports Third Quarter 2022 Results
(GlobeNewswire)
07:00AM
R1 RCM Announces Leadership Succession Plan
(GlobeNewswire)
Nov-02-22 10:01AM
Blade Air Mobility, Inc. (BLDE) Expected to Beat Earnings Estimates: Should You Buy?
(Zacks)
Nov-01-22 10:01AM
R1 RCM Inc. (RCM) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
(Zacks)
Oct-19-22 05:00PM
R1 RCM to Release Third Quarter 2022 Results on November 8
(GlobeNewswire) -5.08%
Oct-18-22 07:25AM
New Strong Buy Stocks for October 18th
(Zacks)
R1 RCM, Inc. engages in the provision of revenue cycle management to healthcare providers. It offers end-to-end, modular revenue cycle, and physician advisory services. The company was founded by Mary Ann Tolan and J. Michael Cline in July 2003 and is headquartered in Murray, UT.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SPARBY JOHN M.PresidentMar 07 '24Sale14.3310,046143,9590Mar 08 07:10 PM
HENNEMAN JOHN B IIIDirectorAug 08 '23Option Exercise2.6150,000130,500122,114Aug 09 04:36 PM
HENNEMAN JOHN B IIIDirectorAug 08 '23Sale17.1750,000858,65072,114Aug 09 04:36 PM
Evans Richard B. Jr.Principal Accounting OfficerJun 12 '23Sale16.8417,000286,229124,007Jun 12 05:52 PM
Evans Richard B. Jr.Principal Accounting OfficerJun 09 '23Sale16.6912,000200,280141,007Jun 12 05:52 PM
SPARBY JOHN M.PresidentMay 10 '23Sale16.3620,000327,280243,827May 12 05:07 PM
open in screener | open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2024 FINVIZ.com. All Rights Reserved.